\
&
Contact us
\
&
Contact us
This was 10 months ago
Locationonline
ProgrammesThis info day aims to inform interested applicants about calls in the new Horizon Europe Widening participation and strengthening the European Research Area (WIDERA) Work Programme 2025. Publication of the WIDERA Work Programme 2025 is expected by the end of April 2025. Forthcoming and open calls for proposals will be included on the European Commission Funding and Tenders portal.
During the info day speakers from the European Commission will present the new call topics. Interested applicants will have an opportunity to ask questions during the event using the code #WIDERA in Slido.
Interested participants for this info day are requested to log in to the research and innovation community platform to watch the event live.
For all up to date information on this info day please visit the announcement on the research and innovation community platform of the European Commission.
More information on the two main components of the WIDERA Work Programme Widening participation and spreading excellence and Reforming and enhancing the European Research and Innovation system
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
